Anti-Mouse/Human TGF-beta1, 2, 3 - Purified In vivo GOLD Functional Grade

Antibody Details

Product Details

Reactivity Species

Human

Host Species

Mouse

Immunogen

Bovine TGFβ isoform 2

Product Concentration

≥ 5.0 mg/ml

Endotoxin Level

≤ 1.0 EU/mg as determined by the LAL method

Purity

≥95% monomer by analytical SEC

⋅

> 95% by SDS Page

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Storage and Handling

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Country of Origin

USA

Shipping

2-8°C

RRID

AB_2737573

Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Specificity

Mouse Anti-Human/Mouse Transforming Growth Factor-Beta 1, 2, 3 (TGF-β1, 2, 3) (Clone 1D11.16.8) recognizes an epitope on Human/Mouse TGF-β1, 2, 3. This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Antigen Details

Protein

2

Ligand/Receptor

Heterodimeric receptor consisting of type I (TbRI) and type II (TbRII).

PubMed

2

Research Area

Apoptosis

.

Cell Biology

.

Cell Death

.

Immunology

.

Neuroinflammation

.

Neuroscience

.

Signal Transduction

.

Tumor Suppressors

References & Citations

1. Guven, M. et al. (2007) Growth Factors 25: 101
2. Schneider, J. et al. (2009) J Investing Med. 57(5):655-61
3. Yu, C. et al. (2009) Biochem Biophys Res Commun. 406(2):204-210

Technical Protocols